Information Provided By:
Fly News Breaks for January 4, 2019
ACOR
Jan 4, 2019 | 07:12 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Acorda Therapeutics to $33 saying FDA approval for the company's lead clinical candidate Inbrija bodes well for 2019. The label does not appear to contain any overly onerous restrictions, Selvaraju tells investors in a research note. He reiterates a Buy rating on Acorda.
News For ACOR From the Last 2 Days
There are no results for your query ACOR